In just seven days ProText Mobility (OTC: TXTM) has soared by more than fivefold after being acquired by South African RSAMMDA.LLC. The biotech company was actually dying because of a lack of funding and research and development projects.
RSAMMDA.LLC is likely to pump Protext with new investments but biotech assets may take more than a year to finish a project whether it is clinical trials or FDA approval.
Current $0.0164 looks so attractive to new investors who are searching for penny stock opportunities. We have already lost a huge chance of getting pretty big returns just in a week. Hopefully, the stock is expected to grow further as the asset management company has a serious interest in it.